Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD

P.G. Aftimos; J. Cortés; F.C. Bidard; V. Kaklamani; A. Bardia; P. Neven; G. Streich; A. Montero; F. Forget; M.A. Mouret Reynier; J. Sohn; D. Taylor; K. Harnden; H. Khong; J. Kocsis; F. Dalenc; P. Dillon; G. Tonini; K.J. Grzegorzewski; J. Lu

doi:10.1016/j.annonc.2022.07.259

YUHSpace

BROWSE

0 155

Cited 0 times in

Elacestrant vs fulvestrant or aromatase inhibitor (AI) in phase III trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs standard of care (SOC) endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC): Subgroup analysis from EMERALD

Authors: P.G. Aftimos ; J. Cortés ; F.C. Bidard ; V. Kaklamani ; A. Bardia ; P. Neven ; G. Streich ; A. Montero ; F. Forget ; M.A. Mouret Reynier ; J. Sohn ; D. Taylor ; K. Harnden ; H. Khong ; J. Kocsis ; F. Dalenc ; P. Dillon ; G. Tonini ; K.J. Grzegorzewski ; J. Lu